Core Viewpoint - The article discusses the legal actions taken against Puli Pharmaceutical due to false reporting of sales revenue and profits, leading to investor claims and a recent appeal by the company against a favorable ruling for investors [1][3]. Financial Misreporting - Puli Pharmaceutical falsely reported sales revenue and profits by fabricating sales of finished and raw pharmaceutical products from 2021 to 2022. In 2021, the company overstated revenue by 436,606,838.34 yuan, which was 28.94% of the reported revenue, and overstated profit by 308,018,435.49 yuan, accounting for 65.88% of the reported profit [1][5]. - In 2022, the company overstated revenue by 456,639,341.72 yuan, representing 25.28% of the reported revenue, and overstated profit by 387,417,257.52 yuan, which was 88.27% of the reported profit [1][4]. Additional Revenue Misstatements - Puli Pharmaceutical also misreported revenue from non-controlling trade activities, leading to an additional overstatement of revenue by 77,997,346.38 yuan in 2021 (5.17% of reported revenue) and 59,259,735.84 yuan in 2022 (3.28% of reported revenue) [2][4]. Legal Proceedings and Investor Claims - The law firm representing investors, Shanghai Jiucheng Law Firm, is continuing to accept claims from investors who purchased Puli Pharmaceutical stock between April 26, 2022, and April 17, 2024, and subsequently sold or held the stock after April 17, 2024 [3][5]. - The firm has a history of successfully representing investors in similar cases, with nearly 200 cases won or settled favorably [3].

Core Viewpoint - The investors' lawsuit against Hainan Puli Pharmaceutical Co., Ltd. has seen some success, with some shareholders winning in the first instance, and the opportunity for further claims remains open as the statute of limitations has not yet expired [1][5]. Summary by Sections Legal Case Background - On March 21, 2025, Puli Pharmaceutical announced it received an administrative penalty decision from the China Securities Regulatory Commission, revealing that from 2021 to 2022, the company falsely recognized sales revenue and profits by fabricating sales of finished and raw pharmaceutical products [2][6]. - In 2021, the company overstated its operating revenue by approximately 440 million yuan, accounting for 28.90% of the disclosed revenue, with an inflated profit of about 290 million yuan, representing 62.06% of the total profit [2][6]. - In 2022, the company similarly overstated its operating revenue by about 460 million yuan, which was 25.23% of the disclosed revenue, leading to an inflated profit of approximately 380 million yuan, or 86.36% of the total profit [2][6]. Financial Misrepresentation - The total overstatement of operating revenue for 2021 was 510 million yuan, which constituted 34.07% of the disclosed revenue, with corresponding inflated costs of about 200 million yuan [3][7]. - For 2022, the total overstatement was also 510 million yuan, making up 28.51% of the disclosed revenue, with inflated costs of approximately 130 million yuan [3][7]. - The company’s annual reports for 2021 and 2022 contained false records, which could lead to legal repercussions for the company [3][7]. Investor Compensation - According to the Supreme People's Court's judicial interpretation on false statements, investors whose rights were harmed by such actions can file lawsuits for compensation, which includes losses from investment differences, commissions, and stamp duty [3][7]. - Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 16, 2024, and still held them at the close on April 16, 2024, are eligible to claim compensation [3][7]. Claim Process - Investors seeking compensation must provide their securities account information, stock reconciliation statements from April 1, 2022, to the present, and contact information [8].